KEY POINTS:

• Claryx launched out of stealth on Aug. 4, 2026 with $3.5 million in pre-seed funding led by Outlander VC, according to the company’s Business Wire release and Fierce Healthcare.

• The company sequences patient infections and hospital environmental samples, including air, sinks and wastewater, to link cases and trace sources, Kurt and Dirk Hackenberger told Fierce Healthcare.

• The peer-reviewed study Claryx cites, published in Clinical Infectious Diseases, sequenced bacterial isolates taken from patients, not the environment, and reported an average of 15 days from culture collection to completed genomic analysis.

• Two authors of that study are publicly affiliated with a competitor, Next Gen Diagnostics, per the journal’s disclosure statement and company announcements.

• Claryx did not name the hospitals using its technology, and its claim of a more than twentyfold reduction in sequencing cost is company-supplied and not independently verified.

A two-year-old startup founded by two brothers said Tuesday it had raised $3.5 million to sell hospitals a service that reads the genomes of the bacteria infecting their patients and matches them against the genomes of the buildings those patients are lying in.

Claryx launched out of stealth on Aug. 4, 2026 with a pre-seed round led by Outlander VC, with participation from Company Ventures, Boost VC, Neon, Mana Ventures, 640 Oxford and Precursor, according to the company’s Business Wire release. Kurt Hackenberger, co-founder and CEO, told Fierce Healthcare in an interview published the same day that the technology is being deployed at multiple leading health systems in New York City.

The company was founded by Kurt Hackenberger and his brother Dirk Hackenberger, the chief science officer, after their grandmother entered a hospital for a routine procedure, developed C. difficile and then sepsis, turning a few hours into three months, according to Fierce Healthcare. The Business Wire release dates that admission to 2004.

What the company says it does

“We’re trying to find pathogens in hospitals before they get into patients,” Dirk Hackenberger told Fierce Healthcare. He said the company sequences the genomes of pathogens isolated by hospital clinical microbiology labs and, separately, the metagenomes of the environment, including building-level wastewater, ward and room-level air samples, and surface and sink swabs, then compares the two.

Fierce Healthcare reported that the platform is called CloneLink and that a continuous air sampler is called AeroScan. The Business Wire release names CloneLink but does not use the name AeroScan.

Claryx says in its release that chemistry Dirk Hackenberger developed during his doctorate cut the most expensive sequencing step by more than twentyfold. He completed that doctorate at McMaster University under Gerard Wright, defending in April 2025, according to the McArthur Lab at McMaster. The International Telegraph could not independently verify the twentyfold figure. [VERIFICATION NEEDED]

“Today we can tell a hospital where an infection came from. We’re building toward a future where it never had to happen in the first place,” Kurt Hackenberger said in the Business Wire release.

The evidence, and what it actually tested

GenomeWeb reported that Claryx’s systems are based on the Enhanced Detection System for Healthcare-Associated Transmission, or EDS-HAT, developed by researchers at the University of Pittsburgh.

That program was evaluated in a study by Alexander Sundermann, Lee Harrison and colleagues published in Clinical Infectious Diseases, online April 30, 2025. The authors reported that 3,921 bacterial isolates from patient infections at UPMC Presbyterian underwent whole-genome sequencing over two years, that 476 of them clustered into 172 outbreaks, and that 95.6% of intervened outbreaks showed no further transmission on that route. They estimated 62 infections and 4.8 deaths avoided and a 3.2-fold return on investment.

Two details matter for how that evidence maps onto Claryx’s product. The authors reported that sequencing was performed on clinical isolates from patients, not on air, water or surface samples. They also reported an average of 15 days from culture collection to completed genomic analysis, with a range of seven to 58 days.

The paper’s disclosure statement records that Sundermann received travel support from Next Gen Diagnostics. Company announcements distributed through Yahoo Finance and Access Newswire state that Sundermann joined Next Gen Diagnostics as director of infection prevention services and that Harrison joined its advisory team. GenomeWeb reported in December 2024 that Next Gen Diagnostics offered its sequencing service at $99 a sample.

The field has other entrants. bioMérieux announced on June 16, 2025 that it had acquired the sequencing solutions and technologies of Day Zero Diagnostics, whose epiXact service also sequences pathogens to establish relatedness in hospital outbreaks, for a total consideration under $25 million.

The market numbers

The Centers for Disease Control and Prevention said in a July 15, 2026 release that on any given day in 2023, about 1 in 38 hospitalized patients had at least one healthcare-associated infection, compared with 1 in 31 in 2015, and that an estimated 518,000 such infections occurred in U.S. hospitals in 2023. The agency presented those figures as evidence of a decline. Fierce Healthcare and Claryx cite the 1 in 38 figure without the comparison.

The $28.4 billion to $45 billion cost range both cite comes from a 2009 CDC report by R. Douglas Scott II, which adjusted its estimates to 2007 dollars. The 7.8-day excess length of stay they cite comes from a 2021 Journal of Hospital Infection study by Stewart and colleagues conducted at two hospitals in NHS Scotland, not in the United States.

Under Medicare’s Hospital-Acquired Condition Reduction Program, CMS reduces payments by 1% for hospitals scoring above the 75th percentile. A University of Michigan policy brief put total annual penalties at approximately $350 million. Kaufman Hall reported that hospitals’ adjusted year-to-date operating margin closed 2025 at 1.3%.

The open question

Whether a pathogen found in a sink caused a patient’s infection is not settled. Constantinides and colleagues, sequencing 46 contemporaneous patient isolates at an Oxford hospital, reported one isolate closely matching a prior sink isolate, and estimated sinks might contribute up to 10% of infections from those organisms on that ward.

Kurt Hackenberger acknowledged the gap to Fierce Healthcare. “The hardest part is getting from the point where we are today to having enough evidence generated to be able to prove exactly that thesis,” he said, adding that the funding would support that work over the next 18 to 24 months.